{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biliary+Diseases&page=26", "query": { "condition": "Biliary Diseases", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 735, "total_pages": 74, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biliary+Diseases&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biliary+Diseases&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T22:42:24.015Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01439698", "title": "Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cholangiocarcinoma", "Pancreatic Cancer", "Bile Duct Cancer", "Biliary Stricture", "Bile Duct Obstruction" ], "interventions": [ { "name": "Radio Frequency ablation Probe", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2011-09", "completion_date": "2018-12-30", "has_results": false, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01439698" }, { "nct_id": "NCT04561453", "title": "Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Biliary Tract Cancer", "Cholangiocarcinoma", "Gallbladder Cancer", "Intrahepatic Cholangiocarcinoma", "Perihilar Cholangiocarcinoma", "Extrahepatic Cholangiocarcinoma", "Hilar Cholangiocarcinoma", "Distal Bile Duct Cancer" ], "interventions": [ { "name": "Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-07-08", "completion_date": "2025-04-04", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 2, "location_summary": "Chicago, Illinois • Seattle, Washington", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04561453" }, { "nct_id": "NCT03929666", "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer" ], "interventions": [ { "name": "ZW25 (Zanidatamab)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2019-08-22", "completion_date": "2025-08-30", "has_results": true, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 11, "location_summary": "Los Angeles, California • Newport Beach, California • Tampa, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03929666" }, { "nct_id": "NCT07221253", "title": "A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biliary Tract Cancer" ], "interventions": [ { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Gemcitabine/Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1100, "start_date": "2025-12-04", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221253" }, { "nct_id": "NCT03937830", "title": "Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Cancer", "Hepatocellular Carcinoma", "Metastatic Hepatocellular Carcinoma" ], "interventions": [ { "name": "durvalumab", "type": "DRUG" }, { "name": "Doxorubicin-Eluting Beads", "type": "DRUG" }, { "name": "TACE", "type": "PROCEDURE" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 27, "start_date": "2021-03-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03937830" }, { "nct_id": "NCT05579444", "title": "Systems Biology of Gastrointestinal and Related Diseases", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ulcerative Colitis", "Crohn Disease", "Obesity", "Colon Polyp", "Eosinophilic Esophagitis", "GERD", "Gastro Esophageal Reflux", "Barrett Esophagus", "Esophageal Cancer", "Gastritis", "Gastric Ulcer", "Duodenal Ulcer", "Intestinal Metaplasia", "Gastric Cancer", "Lymphocytic Colitis", "Microscopic Colitis", "Celiac Sprue", "IBS", "Irritable Bowel Syndrome", "SIBO", "NAFLD", "Gallstone Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Viome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2022-11-11", "completion_date": "2023-11-29", "has_results": false, "last_update_posted_date": "2023-12-15", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 1, "location_summary": "Bothell, Washington", "locations": [ { "city": "Bothell", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579444" }, { "nct_id": "NCT05014672", "title": "A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis", "Liver Stiffness" ], "interventions": [ { "name": "Setanaxib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calliditas Therapeutics Suisse SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2022-02-14", "completion_date": "2024-07-02", "has_results": true, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 29, "location_summary": "Tucson, Arizona • Los Angeles, California • Pasadena, California + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Inverness", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014672" }, { "nct_id": "NCT00107536", "title": "Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2005-10", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107536" }, { "nct_id": "NCT02829918", "title": "Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biliary Tract Cancer", "Biliary Tract Neoplasms" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2016-10-05", "completion_date": "2023-05-24", "has_results": true, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 3, "location_summary": "Duarte, California • Tampa, Florida • Atlanta, Georgia", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02829918" }, { "nct_id": "NCT02702843", "title": "Fluorescent Cholangiography vs White Light for Bile Ducts Identification", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cholecystitis", "Cholelithiasis" ], "interventions": [ { "name": "Laparoscopic cholecystectomy with Xenon light", "type": "PROCEDURE" }, { "name": "Laparoscopic cholecystectomy (fluorescent cholangiography)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 677, "start_date": "2016-04", "completion_date": "2018-08-31", "has_results": true, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-11-15T22:42:24.015Z", "location_count": 2, "location_summary": "Los Angeles, California • Cleveland, Ohio", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702843" } ] }